Related Articles

The article offers a preview on the two diet medications approved by the U.S. Food and Drug Administration (FDA), the Belviq and the combined phentermine and topiramate drug called Qsymia and another drug, the Contrave, which is to be reviewed by the agency after it was rejected in 2011.

Highlights the results of a study conducted at Baylor College of Medicine in Houston, Texas indicating the potency of orlistat to promote weight loss among obese patients. Need for the combination of moderate-calorie diet; Mechanism of the drug's action; Adverse reactions.

Reports on warnings about Chinese weight-loss products from the U.S. Food and Drug Administration. Risks from Chaso Diet Capsules and Chaso Genpi; Deaths in Japan; Danger of the toxic ingredient, aristolochic acid; Lethal combination of fenfluramine and phentermine.